Haplo Peripheral Blood Sct In GVHD Prevention

Inclusion Criteria

• •Men or women ≥ 18 and ≤ 80 years old
• •Diagnosis of hematological malignancy:
• •* Acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) in morphologic complete remission
• •* Myelodysplastic syndrome (MDS), myeloproliferative disorders (MPN), or chronic myelomonocytic leukemic (CMML) with \< 5% blasts in blood or bone marrow
• •* Chemosensitive Hodgkin lymphoma (HL) or Non-Hodgkin lymphoma (NHL)
• •Patients must be undergoing haploidentical allogeneic hematopoietic cell transplantation, defined as 1st or 2nd degree relative with at least 5/10 matching at HLA-A, -B, -C, DR, and DQ.
• •ECOG performance status ≤2
• •Patients with adequate physical function as measured by:
• •* Cardiac: Left ventricular ejection fraction at rest must be ≥ 40%, or shortening fraction \>25%
• •* Hepatic:
• •* Bilirubin ≤ 2.5 mg/dL, except for patients with Gilbert's syndrome or hemolysis
• •* ALT, AST, and Alkaline Phosphatase \< 5 x ULN
• •* Renal: Serum creatinine within normal range, or if serum creatinine is outside normal range, then renal function (measured or estimated creatinine clearance or GFR) ≥ 40mL/min/1.73m2
• •* Pulmonary: DLCO (corrected for hemoglobin), FEV1 and FVC ≥ 50% predicted
• •Ability to understand and the willingness to sign a written informed consent document